{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:55:52Z","timestamp":1786737352626,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Res Pharma Sci"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/1735-5362.293515","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T22:41:34Z","timestamp":1598395294000},"page":"367","source":"Crossref","is-referenced-by-count":7,"title":["Anti-Toxoplasma gondii activity of 5-oxo-hexahydroquinoline derivatives: synthesis, in vitro and in vivo evaluations, and molecular docking analysis"],"prefix":"10.4103","volume":"15","author":[{"given":"Mehdi","family":"Khoshneviszadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadsaeid","family":"Zahedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasem","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Badakhshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sakhteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1735-5362.293515-1","first-page":"e00057","volume-title":"Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice.Clin Microbiol Rev?","author":"Dunay","year":"2018","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-2","first-page":"1292","volume-title":"Annual cost of illness and quality-adjusted life year losses in the United States due to 14 foodborne pathogens.J Food Prot?","author":"Hoffmann","year":"2012","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-3","doi-asserted-by":"crossref","unstructured":"Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical observations. . Int J Parasitol. 2009;39(8):895-901. DOI: 10.1016\/j.ijpara.2009.02.004.","DOI":"10.1016\/j.ijpara.2009.02.004"},{"key":"key-10.4103\/1735-5362.293515-4","first-page":"656","volume-title":"Severe acquired toxoplasmosis caused by wild cycle of Toxoplasma gondii, French Guiana.Emerg Infect Dis?","author":"Carme","year":"2009","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-5","first-page":"e3182,1","volume-title":"Geographic separation of domestic and wild strains of Toxoplasma gondii in French Guiana correlates with a monomorphic version of chromosome1a.PLOS Neglect Trop Dis?","author":"Khan","year":"2014","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-6","first-page":"100016","volume-title":"Structure, composition, and roles of the Toxoplasma gondii oocyst and sporocyst walls.Cell Surf?","author":"Freppel","year":"2019","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-7","doi-asserted-by":"crossref","unstructured":"Dubey JP. The history and life cycle of Toxoplasma gondii. In: Weiss LM, Kim K, editors. The model Apicomplexan-perspectives and methods. 3th ed. New York: Academic Press; 2020. pp. 1-19. DOI: 10.1016\/C2011-0-07157-0.","DOI":"10.1016\/C2011-0-07157-0"},{"key":"key-10.4103\/1735-5362.293515-8","first-page":"1474","volume-title":"An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats.Sci Rep?","author":"Ramakrishnan","year":"2019","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-9","first-page":"25","volume-title":"On the determination of Toxoplasma gondii virulence in mice.Exp Parasitol?","author":"Saraf","year":"2017","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-10","first-page":"e00036,i","volume-title":"Treatment of toxoplasmosis: current options and future perspectives.Food Waterborne Parasitol?","author":"Konstantinovic","year":"20i9","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-11","first-page":"e0178203,1","volume-title":"Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites.PloS One?","author":"Murata","year":"2017","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-12","first-page":"653","volume-title":"Synthesis and biological potentials of quinoline analogues: A review of literature.Mini- Rev Org Chem?","author":"Kumari","year":"2019","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-13","doi-asserted-by":"crossref","unstructured":"Ranjbar S, Edraki N, Firuzi O, Khoshneviszadeh M, Miri R. 5-Oxo-hexahydroquinoline: An attractive scaffold with diverse biological activities. Mol. Divers. 2019;23:471-508. DOI: 10.1007\/s11030-018-9886-4","DOI":"10.1007\/s11030-018-9886-4"},{"key":"key-10.4103\/1735-5362.293515-14","first-page":"136","volume-title":"5-Oxo- hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.Toxicol Appl Pharm?","author":"Ranjbar","year":"2019","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-15","first-page":"1919","volume-title":"Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysis.MedChemComm?","author":"Ranjbar","year":"2017","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-16","first-page":"135","volume-title":"The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection.Exp Parasitol?","author":"Kadri","year":"2014","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-17","first-page":"83","volume-title":"Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens.Nature?","author":"Brinster","year":"2009","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-18","first-page":"11","volume-title":"Increasing pinosylvin production in Escherichia coli by reducing the expression level of the gene fabI-encoded enoyl-acyl carrier protein reductase.Electron J Biotechnol?","author":"Salas-Navarrete","year":"2018","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-19","first-page":"227","volume-title":"Quinolone-based drugs against Toxoplasma gondii and Plasmodium spp.Curr Drug Targets Infect Disord?","author":"Anquetin","year":"2005","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-20","first-page":"109","volume-title":"Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I.Int J Parasitol?","author":"McLeod","year":"2001","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-21","first-page":"109","volume-title":"Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasma gondii growth in vitro.Int J Parasitol?","author":"Radke","year":"2001","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-22","first-page":"15936","volume-title":"Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis.Proc Natl Acad Sci U S A?","author":"Doggett","year":"2012","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-23","first-page":"1109","volume-title":"Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HAT-independent activity against Toxoplasma gondii.Antimicrob Agents Chemother?","author":"Smith","year":"2007","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-24","doi-asserted-by":"crossref","unstructured":"Akins CK, Panicker SE, Cunningham CL. Laboratory animals in research and teaching: Ethics, care, and methods: Am Psychol Assoc. 2005.","DOI":"10.1037\/10830-000"},{"key":"key-10.4103\/1735-5362.293515-25","doi-asserted-by":"crossref","unstructured":"Asgari Q, Keshavarz H, Rezaeian M, Motazedian MH, Shojaee S, Mohebali M, et al. Direct effect of two naphthalene-sulfonyl-indole compounds on Toxoplasma gondii tachyzoite. J Parasitol Res. 2013;2013,1-8. DOI: 10.1155\/2013\/716976.","DOI":"10.1155\/2013\/716976"},{"key":"key-10.4103\/1735-5362.293515-26","doi-asserted-by":"crossref","unstructured":"Buntrock RE. ChemOffice Ultra 7.0. J Chem Inf Model Comput Sci. 2002;42(6):1505-1506. DOI: 10.1021\/ci025575p.","DOI":"10.1021\/ci025575p"},{"key":"key-10.4103\/1735-5362.293515-27","first-page":"455","volume-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.J Comput Chem?","author":"Trott","year":"2010","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-28","first-page":"1639","volume-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function.J Comput Chem?","author":"Morris","year":"1998","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-29","first-page":"6","volume-title":"Identification of dihydroorotate dehydrogenase as a relevant drug target for 1-hydroxyquinolones in Toxoplasma gondii.Mol Biochem Parasitol?","author":"Hegewald","year":"2013","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-30","first-page":"44","volume-title":"Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models.Vet Parasitol?","author":"Barbosa","year":"2012","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-31","first-page":"340","volume-title":"Enrofloxacin and toltrazuril are able to reduce Toxoplasma gondii growth in human BeWo trophoblastic cells and villous explants from human third trimester pregnancy.Front Cell Infect Microbiol?","author":"da","year":"2017","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-32","first-page":"48","volume-title":"Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii.Antimicrob Agents Chemother?","author":"Khan","year":"2001","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-33","first-page":"29179","volume-title":"New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections.S Sci Rep?","author":"McPhillie","year":"2016","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-34","first-page":"128","volume-title":"Antimalarial drug discovery\u2013the path towards eradication.Parasitol?","author":"Burrows","year":"2014","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-35","first-page":"15378","volume-title":"Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.Proc Natl Acad Sci U S A?","author":"Parsons","year":"2011","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-36","first-page":"5940","volume-title":"How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics.J J Biol Chem?","author":"Yao","year":"2015","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-37","first-page":"506","volume-title":"Type II fatty acid synthesis is essential only for malaria parasite late liver stage development.Cell Microbiol?","author":"Vaughan","year":"2009","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-38","first-page":"15","volume-title":"Fatty acid biosynthesis as a drug target in apicomplexan parasites.Current drug targets","author":"Goodman","year":"2007","journal-title":""},{"key":"key-10.4103\/1735-5362.293515-39","first-page":"167","volume-title":"Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum.Nat Med?","author":"Surolia","year":"2001","journal-title":""}],"container-title":["Research in Pharmaceutical Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:53:22Z","timestamp":1786733602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1735-5362.293515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"alternative-id":["293515"],"URL":"https:\/\/doi.org\/10.4103\/1735-5362.293515","relation":{},"ISSN":["1735-5362"],"issn-type":[{"value":"1735-5362","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}